Singapore, Dec. 19 -- MEDI&GENE, a South Korea-based biopharmaceutical company developing therapeutics for metabolic diseases, has entered into a catalyse agreement with EliLillyand Company toadvance anext-generationtherapeuticfor obesity.

MEDI&GENE's discovery platformis designed to unlock novel therapeutic pathways that have the potential to sustain long-term weight maintenance, lean mass maintenance, and durability of desired metabolic effects.

Undertheagreement,Lilly ExploR&D will bring Lilly's expertise in molecule engineering and development to a MEDI&GENE asset, with the goal to advance the programme to clinical trial readiness.

Lilly ExploR&D is part of the Lilly Catalyze360 suite of offerings designed to empower biotech innova...